Compare NBIX & TLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBIX | TLN |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | United States | United States |
| Employees | N/A | 1880 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.2B |
| IPO Year | 1996 | N/A |
| Metric | NBIX | TLN |
|---|---|---|
| Price | $130.61 | $345.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 12 |
| Target Price | $180.82 | ★ $433.50 |
| AVG Volume (30 Days) | ★ 901.1K | 615.1K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 4.67 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $22.85 | $85.30 |
| Revenue Next Year | $10.36 | $10.97 |
| P/E Ratio | ★ $27.09 | $83.51 |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $97.30 | $186.55 |
| 52 Week High | $160.18 | $451.28 |
| Indicator | NBIX | TLN |
|---|---|---|
| Relative Strength Index (RSI) | 50.14 | 56.82 |
| Support Level | $124.29 | $303.75 |
| Resistance Level | $136.23 | $345.29 |
| Average True Range (ATR) | 4.29 | 14.99 |
| MACD | -0.08 | 2.92 |
| Stochastic Oscillator | 59.64 | 94.06 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Talen Energy Corp is an independent power producer and energy infrastructure company based in the United States. It owns and operates several gigawatts of power infrastructure in the United States, including 2.2GW of nuclear power and a dispatchable fossil fleet. The company produces and sells electricity, capacity, and ancillary services into wholesale U.S. power markets, with its generation fleet principally located in the Mid-Atlantic, Ohio, and Montana. Talen's operating segments are: PJM and Others. The PJM segment, which generates maximum revenue, is engaged in electricity generation, marketing activities, and commodity risk and fuel management within the PJM market and is comprised of Susquehanna and Talen's natural gas and coal generation facilities in PJM.